The Patients With CRLM Who Benefit More From Bevacizumab
Conditions
Brief summary
This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive unresectable colorectal cancer liver metastases, providing a favorable approach for precise patient treatment.
Detailed description
Accurately predicting tumor response to targeted therapies is essential for guiding personalized conversion therapy in patients with unresectable colorectal cancer liver metastases (CRLM). Currently, tumor response evaluation criteria are based on assessments made after at least 2-months treatment. Consequently, there is a compelling need to develop baseline tools that can be used to guide therapy selection. Herein, the investigators proposed a deep radiomics-based fusion model which demonstrates high accuracy in predicting the efficacy of bevacizumab in CRLM patients. Further, the investigators observed a significant and positive association between the predicted-responders and longer progression-free survival as well as longer overall survival in CRLM patients treated with bevacizumab. Moreover, the model exhibits high negative prediction value, indicating its potential to accurately identify individuals who are unresponsive to bevacizumab. Thus, our model provides a valuable baseline method for specifically identifying bevacizumab-sensitive CRLM patients, which is offering a clinically convenient approach to guide precise patient treatment.
Interventions
DIAGNOSTIC_TESTDeep radiomics-based fusion model
This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years and ≤75 years; 2. Patients were histologically confirmed for colorectal adenocarcinoma with unresectable liver-limited or liver-dominant metastases 3. PET/CT at baseline were available 4. First line treated with FOLFOX+ bevacizumab.
Exclusion criteria
1. Resectable liver metastases; 2. Wide-type KRAS/NRAS; 3. No measurable liver metastasis; 4. No efficacy assessment; 5. No follow-up information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 2013.10.1-2023.1.1 | Objective response rate of patients with colorectal cancer liver metastases who treated with FOLFOX+bevacizumab/FOLFOX |
| PFS | 2013.10.1-2023.1.1 | Progression-free survival of patients with colorectal cancer liver metastases who treated with FOLFOX+bevacizumab/FOLFOX |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 2013.10.1-2023.1.1 | Overall survival of patients with colorectal cancer liver metastases who treated with FOLFOX+bevacizumab/FOLFOX |
Countries
China
Outcome results
None listed